Business
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Updates from the PLEXI-T™ solid tumor and ALLOHA™ heme Phase 1 clinical trials anticipated by end of year On-track to file IND application for TSC-102-A0301 (CD45; HLA-A*03:01) to FDA in the second half of the year Appointed commercial leader Stephen Camiolo as Senior Vice President, Market Access Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a
About this update from Tscan Therapeutics, Inc.
[{"type":"image","alt":"TScan Therapeutics, Inc.","displaySize":"","headline":null,"caption":"TScan Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":88,"url":"https://media.zenfs.com/en/globenewswire.com/c363c98946cf506a90ed1ea98d7db5fd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oJd2gbDue06Bt1BDI6AStQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c363c98946cf506a90ed1ea98d7db5fd","width":300,"height":88}},"lazy":false},{"type":"text","content":"Updates from the PLEXI-T™ solid tumor and ALLOHA™ heme Phase 1 clinical trials anticipated by end of year","length":105,"tagName":"p"},{"type":"text","content":"On-track to file IND application for TSC-102-A0301 (CD45; HLA-A*03:01) to FDA in the second half of the year","length":108,"tagName":"p"},{"type":"text","content":"Appointed commercial leader Stephen Camiolo as Senior Vice President, Market Access","length":83,"tagName":"p"},{"type":"text","content":"Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027","length":108,"tagName":"p"},{"type":"text","content":"WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the three months ended March 31, 2025, and provided a corporate update.","length":368,"tagName":"p"},{"type":"text","content":""This is an exciting year for TScan as we advance our mission of bringing life-changing T-cell therapies to patients with both heme and solid tumor malignancies,” said Gavin MacBeath, Ph.D., Chief Executive Officer. “In the first quarter, we continued to enroll into singleplex dose levels in our PLEXI-T solid tumor trial. We look forward to dosing our first patient with multiplex therapy soon, and to sharing safety and efficacy data later this year. With respect to our heme program, we remain on track to initiate a registrational trial of TSC-101 in the latter half of the year. We continue to investigate TSC-101 in patients with AML, ALL, and MDS and plan to provide an update on the ALLOHA Phase 1 study, including two-year follow-up on initial patients, by year-end....